News Detail

< Back To News Stories

Our Oncology Department is Excited to Offer Tanovea-CA1 For Our Lymphoma Patients

The U.S. Food and Drug Administration recently announced that it's given conditional approval for the first new animal drug to treat canine lymphoma. Also called lymphosarcoma, lymphomais a type of cancer in dogs. The FDA said the active ingredient in Tanovea-CA1 is rabacfosadine,a substance that kills rapidly growing cancer cells.

Tanovea-CA1 must be prescribed by a licensed veterinarian because professional expertise isneeded to correctly diagnose lymphoma in dogs, determine the best treatment, and managepotential side effects. Tanovea-CA1, which comes in a concentrated form, is diluted and giveninto a vein over 30 minutes. The infusion should be given by or under the supervision of aveterinarian experienced in chemotherapy.

The "CA1" in Tanovea-CA1 means the drug is conditionally approved. Only animal drugsintended for minor species, such as ferrets or fish, or for minor uses in a major species, such as totreat certain types of cancer in dogs, are eligible for conditional approval. Tanovea-CA1'sconditional approval means that when used according to the label, the drug is safe and has a"reasonable expectation of effectiveness" for treating lymphoma in dogs.

At Valley Central, our Oncology Department is excited to add this agent to our current list ofdrugs to treat lymphoma. Please schedule a consultation appointment with our Oncology Department if you have a dog with lymphoma who may benefit from this new treatment.